Taiwan In-Vitro Diagnostics Market Outlook

Taiwan In-Vitro Diagnostics Market by Product & Service (Reagents & Consumables, Instruments & Devices, and Software & Services), by Technique (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology & Coagulation, Microbiology, Urinalysis & Body Fluids, and Other Techniques), by Testing Site / Channel (Central & Reference Laboratories, Hospital & Physician Labs, and Others), by Application (Infectious Diseases, and Others) – Opportunity Analysis and Industry Forecast, 2024–2030

Download PDF

Speak to Our Analyst

Taiwan In-Vitro Diagnostics Market Overview

The Taiwan In-Vitro Diagnostics Market size was valued at USD 0.77 billion in 2023, and is predicted to reach USD 1.39 billion by 2030, at a CAGR of 8.4% from 2024 to 2030. In-vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions.

IVD tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology. These tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, IVD tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics.

Also, immunodiagnostic experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.

Increased Geriatric Population Rates Drive the Market Growth

The significant rise in the geriatric’s population drives the growth of the in-vitro diagnostics market in the country. According to East Asia Forum, the proportion of Taiwan's population aged above 65 has surged from 2.5 percent in the 1950s to 17.56 percent in 2021.

Projections by the National Development Council suggest that Taiwan will emerge as one of the world's oldest nations by 2060, with the elderly population comprising an estimated 41.4 percent of the total population. With a significant portion of the population entering older age, there is a heightened demand for diagnostic technologies to address age-related health issues and diseases. In particular, the prevalence of chronic conditions and age-related illnesses among the elderly population necessitates frequent monitoring, early detection, and personalized treatment approaches, all of which are facilitated by IVD solutions.

Rising Prevalence of Diabetes Boosts the Market Demand in Taiwan

The escalation in the prevalence of diabetes significantly drives the Taiwan in-vitro diagnostics market demand. International Diabetes Federation reported that, between 2011 and 2045, the number of individuals diagnosed with diabetes in Taiwan is to rise significantly. In 2011, there were approximately 1,664 thousand people with diabetes, and this number is projected to rise substantially by 2045, reaching an estimated 3,030 thousand individuals. As the diabetic population continues to grow, there is an increasing demand for precise and efficient diagnostic methods such as IVD to monitor blood glucose levels, detect complications, and tailor treatment plans effectively.

High Research, Development, and Regulatory Approval Costs Hinder the Market Growth

High costs associated with research, development, and regulatory approval are significant factors restraining the Taiwan IVD market growth. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development.

This investment often encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability. Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from market expansion.

Introduction of Point-of-Care Testing Solutions in IVD Creates Market Opportunity

Point-of-care testing (POCT) is poised to be a significant driver of the Taiwan in-vitro diagnostics market expansion in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings.

With POCT technologies offering rapid tests for infectious diseases, cardiac markers, glucose monitoring, pregnancy testing, and more, healthcare providers can quickly assess patients' conditions and make timely treatment decisions. By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.

Competitive Landscape

The promising players operating in the Taiwan in-vitro diagnostics industry include Roche Diagnostics Taiwan, Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation, ThermFisher Scientific Inc., Becton Dickinson (BD) Taiwan, bioMérieux, Sysmex Corporation, Qiagen Taiwan, Bio‑Rad Laboratories, Inc., ApexBiTechnology, Generi Biotech, General Biologicals Corporation (GBC), Medigen Vaccine Biologics, Phalanx Biotech Group, and others.

Taiwan In-Vitro Diagnostics Market Key Segments

By Product & Service

Reagents & Consumables
- Clinical Chemistry Reagents
- Immunoassay Reagents (ELISA/CLIA)
- Molecular Master Mixes
- Hematology Controls
Instruments & Devices
- Chemistry Analyzers
- Immunoassay Systems
- Molecular Thermocyclers/Sequencers
- Hematology Analyzers
- POC Devices
Software & Services
- LIS, Data Analytics
- CRO/Testing Services

By Technique

Clinical Chemistry
- Metabolites
- Electrolytes
- Enzymes
Immunoassays
- ELISA / CLIA / CMIA
- Lateral-flow Rapid Tests
- Immunofluorescence
Molecular Diagnostics
- PCR
- Isothermal NAAT
- NGS
- In-situ Hybridization
Hematology & Coagulation
- CBC Analyzers
- Coagulation Panels
Microbiology
- Culture & Sensitivity
- MALDI-TOF
- Molecular ID
Urinalysis & Body Fluids
Other Techniques

By Testing Site / Channel

Central & Reference Laboratories
Hospital & Physician Labs
Point-of-Care & Retail
Home & Self-Testing

By Application / Disease Area

Infectious Diseases
Oncology
Cardiovascular Health
Endocrinology & Diabetes
Nephrology
Genetic & Prenatal Testing
Autoimmune Disorders
Drug Monitoring & Toxicology
Blood Screening & Typing
Other Indications

Key Players

Roche Diagnostics Taiwan
Abbott Laboratories
Siemens Healthineers AG
Danaher Corporation
ThermFisher Scientific Inc.
Becton Dickinson (BD) Taiwan
bioMérieux
Sysmex Corporation
Qiagen Taiwan
Bio‑Rad Laboratories, Inc.
ApexBiTechnology
Generi Biotech
General Biologicals Corporation (GBC)
Medigen Vaccine Biologics
Phalanx Biotech Group

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Market Size Value in 2023	USD 0.77 billion
Revenue Forecast in 2030	USD 1.39 billion
Value Growth Rate	CAGR of 8.4% from 2024 to 2030
Analysis Period	2023–2030
Base Year Considered	2023
Forecast Period	2024–2030
Market Size Estimation	Billion (USD)
Growth Factors	Increased Geriatric Population Rates Drives Market Growth. Rising Prevalence of Diabetes Boosts the Market Growth in Taiwan.
Companies Profiled	15
Customization Scope	Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.

1. 1.1 REPORT DESCRIPTION
2. 1.2 RESEARCH METHODOLOGY
3. 1. 1.2.1 SECONDARY RESEARCH
  2. 1.2.2 DATA ANALYSIS FRAMEWORK
  3. 1.2.3 MARKET SIZE ESTIMATION
  4. 1.2.4 FORECASTING
  5. 1.2.5 PRIMARY RESEARCH AND DATA VALIDATION

1. 2.1. MARKET SNAPSHOT, 2024 - 2030, BILLION USD

1. 3.1 BARGAINING POWER OF SUPPLIERS
2. 3.2 BARGAINING POWER OF BUYERS
3. 3.3 DEGREE OF COMPETITION
4. 3.4 THREAT OF SUBSTITUTE
5. 3.5 THREAT OF NEW ENTRANTS

1. 4.1 MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2024

1. 5.1 GROWTH DRIVERS
2. 1. 5.1.1 INCREASED GERIATRIC POPULATION RATES DRIVE THE MARKET GROWTH
  2. 5.1.2 RISING PREVALENCE OF DIABETES BOOSTS THE MARKET DEMAND IN TAIWAN
3. 5.2 CHALLENGES
4. 1. 5.2.1 HIGH RESEARCH, DEVELOPMENT, AND REGULATORY APPROVAL COSTS HINDER THE MARKET GROWTH
5. 5.3 OPPORTUNITIES
6. 1. 5.3.1 INTRODUCTION OF POINT-OF-CARE TESTING SOLUTIONS IN IVD CREATES MARKET OPPORTUNITY

1. 6.1 OVERVIEW
2. 6.2 REAGENTS AND CONSUMABLES MARKET
3. 1. 6.2.1 CLINICAL CHEMISTRY REAGENTS
  2. 6.2.2 IMMUNOASSAY REAGENTS (ELISA/CLIA)
  3. 6.2.3 MOLECULAR MASTER MIXES
  4. 6.2.4 HEMATOLOGY CONTROLS
4. 6.3 INSTRUMENTS AND DEVICES MARKET
5. 1. 6.3.1 CHEMISTRY ANALYZERS
  2. 6.3.2 IMMUNOASSAY SYSTEMS
  3. 6.3.3 MOLECULAR THERMOCYCLERS/SEQUENCERS
  4. 6.3.4 HEMATOLOGY ANALYZERS
  5. 6.3.5 POC DEVICES
6. 6.4 SOFTWARE AND SERVICES MARKET
7. 1. 6.4.1 LIS DATA ANALYTICS
  2. 6.4.2 CRO/TESTING SERVICES

1. 7.1 OVERVIEW
2. 7.2 CLINICAL CHEMISTRY MARKET
3. 1. 7.2.1 METABOLITES
  2. 7.2.2 ELECTROLYTES
  3. 7.2.3 ENZYMES
4. 7.3 IMMUNOASSAYS MARKET
5. 1. 7.3.1 ELISA / CLIA / CMIA
  2. 7.3.2 LATERAL-FLOW RAPID TESTS
  3. 7.3.3 IMMUNOFLUORESCENCE
6. 7.4 MOLECULAR DIAGNOSTICS MARKET
7. 1. 7.4.1 PCR
  2. 7.4.2 ISOTHERMAL NAAT
  3. 7.4.3 NGS
  4. 7.4.4 IN-SITU HYBRIDIZATION
8. 7.5 HEMATOLOGY AND COAGULATION MARKET
9. 1. 7.5.1 CBC ANALYZERS
  2. 7.5.2 COAGULATION PANELS
10. 7.6 MICROBIOLOGY MARKET
11. 1. 7.6.1 CULTURE AND SENSITIVITY
  2. 7.6.2 MALDI-TOF
  3. 7.6.3 MOLECULAR ID
12. 7.7 URINALYSIS AND BODY FLUIDS MARKET
13. 7.8 OTHER TECHNIQUES MARKET

1. 8.1 OVERVIEW
2. 8.2 CENTRAL AND REFERENCE LABORATORIES MARKET
3. 8.3 HOSPITAL AND PHYSICIAN LABS MARKET
4. 8.4 POINT-OF-CARE AND RETAIL MARKET
5. 8.5 HOME AND SELF-TESTING MARKET

1. 9.1 OVERVIEW
2. 9.2 INFECTIOUS DISEASES MARKET
3. 9.3 ONCOLOGY MARKET
4. 9.4 CARDIOVASCULAR HEALTH MARKET
5. 9.5 ENDOCRINOLOGY AND DIABETES MARKET
6. 9.6 NEPHROLOGY MARKET
7. 9.7 GENETIC AND PRENATAL TESTING MARKET
8. 9.8 AUTOIMMUNE DISORDERS MARKET
9. 9.9 DRUG MONITORING AND TOXICOLOGY MARKET
10. 9.10 BLOOD SCREENING AND TYPING MARKET
11. 9.11 OTHER INDICATIONS MARKET

1. 10.1 ROCHE DIAGNOSTICS TAIWAN
2. 1. 10.1.1 COMPANY OVERVIEW
  2. 10.1.2 COMPANY SNAPSHOT
  3. 10.1.3 OPERATING BUSINESS SEGMENTS
  4. 10.1.4 PRODUCT PORTFOLIO
  5. 10.1.5 BUSINESS PERFORMANCE
  6. 10.1.6 BUSINESS SEGMENTS
  7. 10.1.7 GEOGRAPHIC SEGMENTS
  8. 10.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.1.9 PRIMARY MARKET COMPETITORS
3. 10.2 ABBOTT LABORATORIES
4. 1. 10.2.1 COMPANY OVERVIEW
  2. 10.2.2 COMPANY SNAPSHOT
  3. 10.2.3 OPERATING BUSINESS SEGMENTS
  4. 10.2.4 PRODUCT PORTFOLIO
  5. 10.2.5 BUSINESS PERFORMANCE
  6. 10.2.6 BUSINESS SEGMENTS
  7. 10.2.7 GEOGRAPHIC SEGMENTS
  8. 10.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.2.9 PRIMARY MARKET COMPETITORS
5. 10.3 SIEMENS HEALTHINEERS AG
6. 1. 10.3.1 COMPANY OVERVIEW
  2. 10.3.2 COMPANY SNAPSHOT
  3. 10.3.3 OPERATING BUSINESS SEGMENTS
  4. 10.3.4 PRODUCT PORTFOLIO
  5. 10.3.5 BUSINESS PERFORMANCE
  6. 10.3.6 BUSINESS SEGMENTS
  7. 10.3.7 GEOGRAPHIC SEGMENTS
  8. 10.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.3.9 PRIMARY MARKET COMPETITORS
7. 10.4 DANAHER CORPORATION
8. 1. 10.4.1 COMPANY OVERVIEW
  2. 10.4.2 COMPANY SNAPSHOT
  3. 10.4.3 OPERATING BUSINESS SEGMENTS
  4. 10.4.4 PRODUCT PORTFOLIO
  5. 10.4.5 BUSINESS PERFORMANCE
  6. 10.4.6 BUSINESS SEGMENTS
  7. 10.4.7 GEOGRAPHIC SEGMENTS
  8. 10.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.4.9 PRIMARY MARKET COMPETITORS
9. 10.5 THERMO FISHER SCIENTIFIC INC.
10. 1. 10.5.1 COMPANY OVERVIEW
  2. 10.5.2 COMPANY SNAPSHOT
  3. 10.5.3 OPERATING BUSINESS SEGMENTS
  4. 10.5.4 PRODUCT PORTFOLIO
  5. 10.5.5 BUSINESS PERFORMANCE
  6. 10.5.6 BUSINESS SEGMENTS
  7. 10.5.7 GEOGRAPHIC SEGMENTS
  8. 10.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.5.9 PRIMARY MARKET COMPETITORS
11. 10.6 BECTON DICKINSON (BD) TAIWAN
12. 1. 10.6.1 COMPANY OVERVIEW
  2. 10.6.2 COMPANY SNAPSHOT
  3. 10.6.3 OPERATING BUSINESS SEGMENTS
  4. 10.6.4 PRODUCT PORTFOLIO
  5. 10.6.5 BUSINESS PERFORMANCE
  6. 10.6.6 BUSINESS SEGMENTS
  7. 10.6.7 GEOGRAPHIC SEGMENTS
  8. 10.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.6.9 PRIMARY MARKET COMPETITORS
13. 10.7 BIOMÉRIEUX
14. 1. 10.7.1 COMPANY OVERVIEW
  2. 10.7.2 COMPANY SNAPSHOT
  3. 10.7.3 OPERATING BUSINESS SEGMENTS
  4. 10.7.4 PRODUCT PORTFOLIO
  5. 10.7.5 BUSINESS PERFORMANCE
  6. 10.7.6 BUSINESS SEGMENTS
  7. 10.7.7 GEOGRAPHIC SEGMENTS
  8. 10.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.7.9 PRIMARY MARKET COMPETITORS
15. 10.8 SYSMEX CORPORATION
16. 1. 10.8.1 COMPANY OVERVIEW
  2. 10.8.2 COMPANY SNAPSHOT
  3. 10.8.3 OPERATING BUSINESS SEGMENTS
  4. 10.8.4 PRODUCT PORTFOLIO
  5. 10.8.5 BUSINESS PERFORMANCE
  6. 10.8.6 BUSINESS SEGMENTS
  7. 10.8.7 GEOGRAPHIC SEGMENTS
  8. 10.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.8.9 PRIMARY MARKET COMPETITORS
17. 10.9 QIAGEN TAIWAN
18. 1. 10.9.1 COMPANY OVERVIEW
  2. 10.9.2 COMPANY SNAPSHOT
  3. 10.9.3 OPERATING BUSINESS SEGMENTS
  4. 10.9.4 PRODUCT PORTFOLIO
  5. 10.9.5 BUSINESS PERFORMANCE
  6. 10.9.6 BUSINESS SEGMENTS
  7. 10.9.7 GEOGRAPHIC SEGMENTS
  8. 10.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.9.9 PRIMARY MARKET COMPETITORS
19. 10.10 BIO-RAD LABORATORIES, INC.
20. 1. 10.10.1 COMPANY OVERVIEW
  2. 10.10.2 COMPANY SNAPSHOT
  3. 10.10.3 OPERATING BUSINESS SEGMENTS
  4. 10.10.4 PRODUCT PORTFOLIO
  5. 10.10.5 BUSINESS PERFORMANCE
  6. 10.10.6 BUSINESS SEGMENTS
  7. 10.10.7 GEOGRAPHIC SEGMENTS
  8. 10.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.10.9 PRIMARY MARKET COMPETITORS
21. 10.11 APEXBITECHNOLOGY
22. 1. 10.11.1 COMPANY OVERVIEW
  2. 10.11.2 COMPANY SNAPSHOT
  3. 10.11.3 OPERATING BUSINESS SEGMENTS
  4. 10.11.4 PRODUCT PORTFOLIO
  5. 10.11.5 BUSINESS PERFORMANCE
  6. 10.11.6 BUSINESS SEGMENTS
  7. 10.11.7 GEOGRAPHIC SEGMENTS
  8. 10.11.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.11.9 PRIMARY MARKET COMPETITORS
23. 10.12 GENERI BIOTECH
24. 1. 10.12.1 COMPANY OVERVIEW
  2. 10.12.2 COMPANY SNAPSHOT
  3. 10.12.3 OPERATING BUSINESS SEGMENTS
  4. 10.12.4 PRODUCT PORTFOLIO
  5. 10.12.5 BUSINESS PERFORMANCE
  6. 10.12.6 BUSINESS SEGMENTS
  7. 10.12.7 GEOGRAPHIC SEGMENTS
  8. 10.12.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.12.9 PRIMARY MARKET COMPETITORS
25. 10.13 GENERAL BIOLOGICALS CORPORATION (GBC)
26. 1. 10.13.1 COMPANY OVERVIEW
  2. 10.13.2 COMPANY SNAPSHOT
  3. 10.13.3 OPERATING BUSINESS SEGMENTS
  4. 10.13.4 PRODUCT PORTFOLIO
  5. 10.13.5 BUSINESS PERFORMANCE
  6. 10.13.6 BUSINESS SEGMENTS
  7. 10.13.7 GEOGRAPHIC SEGMENTS
  8. 10.13.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.13.9 PRIMARY MARKET COMPETITORS
27. 10.14 MEDIGEN VACCINE BIOLOGICS
28. 1. 10.14.1 COMPANY OVERVIEW
  2. 10.14.2 COMPANY SNAPSHOT
  3. 10.14.3 OPERATING BUSINESS SEGMENTS
  4. 10.14.4 PRODUCT PORTFOLIO
  5. 10.14.5 BUSINESS PERFORMANCE
  6. 10.14.6 BUSINESS SEGMENTS
  7. 10.14.7 GEOGRAPHIC SEGMENTS
  8. 10.14.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.14.9 PRIMARY MARKET COMPETITORS
29. 10.15 PHALANX BIOTECH GROUP
30. 1. 10.15.1 COMPANY OVERVIEW
  2. 10.15.2 COMPANY SNAPSHOT
  3. 10.15.3 OPERATING BUSINESS SEGMENTS
  4. 10.15.4 PRODUCT PORTFOLIO
  5. 10.15.5 BUSINESS PERFORMANCE
  6. 10.15.6 BUSINESS SEGMENTS
  7. 10.15.7 GEOGRAPHIC SEGMENTS
  8. 10.15.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.15.9 PRIMARY MARKET COMPETITORS

TABLE 1. TAIWAN IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT AND SERVICE, 2024-2030, (BILLION USD)
TABLE 2. REAGENTS AND CONSUMABLES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 3. CLINICAL CHEMISTRY REAGENTS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 4. IMMUNOASSAY REAGENTS (ELISA/CLIA), MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 5. MOLECULAR MASTER MIXES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 6. HEMATOLOGY CONTROLS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 7. INSTRUMENTS AND DEVICES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 8. CHEMISTRY ANALYZERS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 9. IMMUNOASSAY SYSTEMS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 10. MOLECULAR THERMOCYCLERS/SEQUENCERS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 11. HEMATOLOGY ANALYZERS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 12. POC DEVICES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 13. SOFTWARE AND SERVICES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 14. LIS DATA ANALYTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 15. CRO/TESTING SERVICES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 16. TAIWAN IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
TABLE 17. CLINICAL CHEMISTRY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 18. METABOLITES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 19. ELECTROLYTES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 20. ENZYMES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 21. IMMUNOASSAYS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 22. ELISA / CLIA / CMIA, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 23. LATERAL-FLOW RAPID TESTS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 24. IMMUNOFLUORESCENCE, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 25. MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 26. PCR, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 27. ISOTHERMAL NAAT, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 28. NGS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 29. IN-SITU HYBRIDIZATION, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 30. HEMATOLOGY AND COAGULATION, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 31. CBC ANALYZERS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 32. COAGULATION PANELS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 33. MICROBIOLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 34. CULTURE AND SENSITIVITY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 35. MALDI-TOF, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 36. MOLECULAR ID, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 37. URINALYSIS AND BODY FLUIDS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 38. OTHER TECHNIQUES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 39. TAIWAN IN-VITRO DIAGNOSTICS MARKET VALUE, BY TESTING SITE / CHANNEL, 2024-2030, (BILLION USD)
TABLE 40. CENTRAL AND REFERENCE LABORATORIES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 41. HOSPITAL AND PHYSICIAN LABS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 42. POINT-OF-CARE AND RETAIL, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 43. HOME AND SELF-TESTING, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 44. TAIWAN IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION / DISEASE AREA, 2024-2030, (BILLION USD)
TABLE 45. INFECTIOUS DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 46. ONCOLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 47. CARDIOVASCULAR HEALTH, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 48. ENDOCRINOLOGY AND DIABETES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 49. NEPHROLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 50. GENETIC AND PRENATAL TESTING, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 51. AUTOIMMUNE DISORDERS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 52. DRUG MONITORING AND TOXICOLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 53. BLOOD SCREENING AND TYPING, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 54. OTHER INDICATIONS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 55. ROCHE DIAGNOSTICS TAIWAN: COMPANY SNAPSHOT
TABLE 56. ROCHE DIAGNOSTICS TAIWAN: OPERATING BUSINESS SEGMENTS
TABLE 57. ROCHE DIAGNOSTICS TAIWAN: PRODUCT PORTFOLIO
TABLE 58. ROCHE DIAGNOSTICS TAIWAN: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 59. ROCHE DIAGNOSTICS TAIWAN: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 60. ROCHE DIAGNOSTICS TAIWAN: KEY STRATERGY
TABLE 61. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 62. ABBOTT LABORATORIES: OPERATING BUSINESS SEGMENTS
TABLE 63. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 64. ABBOTT LABORATORIES: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 65. ABBOTT LABORATORIES: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 66. ABBOTT LABORATORIES: KEY STRATERGY
TABLE 67. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
TABLE 68. SIEMENS HEALTHINEERS AG: OPERATING BUSINESS SEGMENTS
TABLE 69. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO
TABLE 70. SIEMENS HEALTHINEERS AG: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 71. SIEMENS HEALTHINEERS AG: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 72. SIEMENS HEALTHINEERS AG: KEY STRATERGY
TABLE 73. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 74. DANAHER CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 75. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 76. DANAHER CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 77. DANAHER CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 78. DANAHER CORPORATION: KEY STRATERGY
TABLE 79. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 80. THERMO FISHER SCIENTIFIC INC.: OPERATING BUSINESS SEGMENTS
TABLE 81. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 82. THERMO FISHER SCIENTIFIC INC.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 83. THERMO FISHER SCIENTIFIC INC.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 84. THERMO FISHER SCIENTIFIC INC.: KEY STRATERGY
TABLE 85. BECTON DICKINSON (BD) TAIWAN: COMPANY SNAPSHOT
TABLE 86. BECTON DICKINSON (BD) TAIWAN: OPERATING BUSINESS SEGMENTS
TABLE 87. BECTON DICKINSON (BD) TAIWAN: PRODUCT PORTFOLIO
TABLE 88. BECTON DICKINSON (BD) TAIWAN: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 89. BECTON DICKINSON (BD) TAIWAN: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 90. BECTON DICKINSON (BD) TAIWAN: KEY STRATERGY
TABLE 91. BIOMéRIEUX: COMPANY SNAPSHOT
TABLE 92. BIOMéRIEUX: OPERATING BUSINESS SEGMENTS
TABLE 93. BIOMéRIEUX: PRODUCT PORTFOLIO
TABLE 94. BIOMéRIEUX: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 95. BIOMéRIEUX: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 96. BIOMéRIEUX: KEY STRATERGY
TABLE 97. SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 98. SYSMEX CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 99. SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 100. SYSMEX CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 101. SYSMEX CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 102. SYSMEX CORPORATION: KEY STRATERGY
TABLE 103. QIAGEN TAIWAN: COMPANY SNAPSHOT
TABLE 104. QIAGEN TAIWAN: OPERATING BUSINESS SEGMENTS
TABLE 105. QIAGEN TAIWAN: PRODUCT PORTFOLIO
TABLE 106. QIAGEN TAIWAN: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 107. QIAGEN TAIWAN: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 108. QIAGEN TAIWAN: KEY STRATERGY
TABLE 109. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 110. BIO-RAD LABORATORIES, INC.: OPERATING BUSINESS SEGMENTS
TABLE 111. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 112. BIO-RAD LABORATORIES, INC.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 113. BIO-RAD LABORATORIES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 114. BIO-RAD LABORATORIES, INC.: KEY STRATERGY
TABLE 115. APEXBITECHNOLOGY: COMPANY SNAPSHOT
TABLE 116. APEXBITECHNOLOGY: OPERATING BUSINESS SEGMENTS
TABLE 117. APEXBITECHNOLOGY: PRODUCT PORTFOLIO
TABLE 118. APEXBITECHNOLOGY: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 119. APEXBITECHNOLOGY: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 120. APEXBITECHNOLOGY: KEY STRATERGY
TABLE 121. GENERI BIOTECH: COMPANY SNAPSHOT
TABLE 122. GENERI BIOTECH: OPERATING BUSINESS SEGMENTS
TABLE 123. GENERI BIOTECH: PRODUCT PORTFOLIO
TABLE 124. GENERI BIOTECH: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 125. GENERI BIOTECH: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 126. GENERI BIOTECH: KEY STRATERGY
TABLE 127. GENERAL BIOLOGICALS CORPORATION (GBC): COMPANY SNAPSHOT
TABLE 128. GENERAL BIOLOGICALS CORPORATION (GBC): OPERATING BUSINESS SEGMENTS
TABLE 129. GENERAL BIOLOGICALS CORPORATION (GBC): PRODUCT PORTFOLIO
TABLE 130. GENERAL BIOLOGICALS CORPORATION (GBC): SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 131. GENERAL BIOLOGICALS CORPORATION (GBC): SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 132. GENERAL BIOLOGICALS CORPORATION (GBC): KEY STRATERGY
TABLE 133. MEDIGEN VACCINE BIOLOGICS: COMPANY SNAPSHOT
TABLE 134. MEDIGEN VACCINE BIOLOGICS: OPERATING BUSINESS SEGMENTS
TABLE 135. MEDIGEN VACCINE BIOLOGICS: PRODUCT PORTFOLIO
TABLE 136. MEDIGEN VACCINE BIOLOGICS: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 137. MEDIGEN VACCINE BIOLOGICS: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 138. MEDIGEN VACCINE BIOLOGICS: KEY STRATERGY
TABLE 139. PHALANX BIOTECH GROUP: COMPANY SNAPSHOT
TABLE 140. PHALANX BIOTECH GROUP: OPERATING BUSINESS SEGMENTS
TABLE 141. PHALANX BIOTECH GROUP: PRODUCT PORTFOLIO
TABLE 142. PHALANX BIOTECH GROUP: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 143. PHALANX BIOTECH GROUP: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 144. PHALANX BIOTECH GROUP: KEY STRATERGY

FIGURE 1. BARGAINING POWER OF SUPPLIERS
FIGURE 2. BARGAINING POWER OF BUYERS
FIGURE 3. DEGREE OF COMPETITION
FIGURE 4. THREAT OF SUBSTITUTE
FIGURE 5. THREAT OF NEW ENTRANTS
FIGURE 6. TAIWAN IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT AND SERVICE, 2024-2030, (BILLION USD)
FIGURE 7. REAGENTS AND CONSUMABLES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 8. CLINICAL CHEMISTRY REAGENTS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 9. IMMUNOASSAY REAGENTS (ELISA/CLIA), MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 10. MOLECULAR MASTER MIXES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 11. HEMATOLOGY CONTROLS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 12. INSTRUMENTS AND DEVICES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 13. CHEMISTRY ANALYZERS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 14. IMMUNOASSAY SYSTEMS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 15. MOLECULAR THERMOCYCLERS/SEQUENCERS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 16. HEMATOLOGY ANALYZERS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 17. POC DEVICES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 18. SOFTWARE AND SERVICES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 19. LIS DATA ANALYTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 20. CRO/TESTING SERVICES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 21. TAIWAN IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
FIGURE 22. CLINICAL CHEMISTRY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 23. METABOLITES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 24. ELECTROLYTES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 25. ENZYMES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 26. IMMUNOASSAYS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 27. ELISA / CLIA / CMIA, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 28. LATERAL-FLOW RAPID TESTS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 29. IMMUNOFLUORESCENCE, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 30. MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 31. PCR, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 32. ISOTHERMAL NAAT, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 33. NGS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 34. IN-SITU HYBRIDIZATION, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 35. HEMATOLOGY AND COAGULATION, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 36. CBC ANALYZERS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 37. COAGULATION PANELS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 38. MICROBIOLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 39. CULTURE AND SENSITIVITY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 40. MALDI-TOF, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 41. MOLECULAR ID, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 42. URINALYSIS AND BODY FLUIDS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 43. OTHER TECHNIQUES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 44. TAIWAN IN-VITRO DIAGNOSTICS MARKET VALUE, BY TESTING SITE / CHANNEL, 2024-2030, (BILLION USD)
FIGURE 45. CENTRAL AND REFERENCE LABORATORIES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 46. HOSPITAL AND PHYSICIAN LABS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 47. POINT-OF-CARE AND RETAIL, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 48. HOME AND SELF-TESTING, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 49. TAIWAN IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION / DISEASE AREA, 2024-2030, (BILLION USD)
FIGURE 50. INFECTIOUS DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 51. ONCOLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 52. CARDIOVASCULAR HEALTH, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 53. ENDOCRINOLOGY AND DIABETES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 54. NEPHROLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 55. GENETIC AND PRENATAL TESTING, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 56. AUTOIMMUNE DISORDERS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 57. DRUG MONITORING AND TOXICOLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 58. BLOOD SCREENING AND TYPING, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 59. OTHER INDICATIONS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 60. ROCHE DIAGNOSTICS TAIWAN: NET SALES, (2022-2024)
FIGURE 61. ROCHE DIAGNOSTICS TAIWAN: PRIMARY MARKET COMPETITORS
FIGURE 62. ABBOTT LABORATORIES: NET SALES, (2022-2024)
FIGURE 63. ABBOTT LABORATORIES: PRIMARY MARKET COMPETITORS
FIGURE 64. SIEMENS HEALTHINEERS AG: NET SALES, (2022-2024)
FIGURE 65. SIEMENS HEALTHINEERS AG: PRIMARY MARKET COMPETITORS
FIGURE 66. DANAHER CORPORATION: NET SALES, (2022-2024)
FIGURE 67. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 68. THERMO FISHER SCIENTIFIC INC.: NET SALES, (2022-2024)
FIGURE 69. THERMO FISHER SCIENTIFIC INC.: PRIMARY MARKET COMPETITORS
FIGURE 70. BECTON DICKINSON (BD) TAIWAN: NET SALES, (2022-2024)
FIGURE 71. BECTON DICKINSON (BD) TAIWAN: PRIMARY MARKET COMPETITORS
FIGURE 72. BIOMéRIEUX: NET SALES, (2022-2024)
FIGURE 73. BIOMéRIEUX: PRIMARY MARKET COMPETITORS
FIGURE 74. SYSMEX CORPORATION: NET SALES, (2022-2024)
FIGURE 75. SYSMEX CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 76. QIAGEN TAIWAN: NET SALES, (2022-2024)
FIGURE 77. QIAGEN TAIWAN: PRIMARY MARKET COMPETITORS
FIGURE 78. BIO-RAD LABORATORIES, INC.: NET SALES, (2022-2024)
FIGURE 79. BIO-RAD LABORATORIES, INC.: PRIMARY MARKET COMPETITORS
FIGURE 80. APEXBITECHNOLOGY: NET SALES, (2022-2024)
FIGURE 81. APEXBITECHNOLOGY: PRIMARY MARKET COMPETITORS
FIGURE 82. GENERI BIOTECH: NET SALES, (2022-2024)
FIGURE 83. GENERI BIOTECH: PRIMARY MARKET COMPETITORS
FIGURE 84. GENERAL BIOLOGICALS CORPORATION (GBC): NET SALES, (2022-2024)
FIGURE 85. GENERAL BIOLOGICALS CORPORATION (GBC): PRIMARY MARKET COMPETITORS
FIGURE 86. MEDIGEN VACCINE BIOLOGICS: NET SALES, (2022-2024)
FIGURE 87. MEDIGEN VACCINE BIOLOGICS: PRIMARY MARKET COMPETITORS
FIGURE 88. PHALANX BIOTECH GROUP: NET SALES, (2022-2024)
FIGURE 89. PHALANX BIOTECH GROUP: PRIMARY MARKET COMPETITORS

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

SWOT Analysis

We conduct SWOT analysis to understand market trends, identify potential threats, capitalize on opportunities, and assess our strengths and weaknesses.

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.

Frequently Asked Questions

The Taiwan in-vitro diagnostics market revenue is estimated to reach USD 1.39 billion by 2030.

The key players operating in the Taiwan in-vitro diagnostics industry include Roche Diagnostics Taiwan, Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation, ThermFisher Scientific Inc., Becton Dickinson (BD) Taiwan, bioMérieux, Sysmex Corporation, Qiagen Taiwan, Bio‑Rad Laboratories, Inc., ApexBiTechnology, Generi Biotech, General Biologicals Corporation (GBC), Medigen Vaccine Biologics, Phalanx Biotech Group, and others.

The Taiwan in-vitro diagnostics market size was estimated at USD 0.77 billion in 2023.

High costs associated with research, development, and regulatory approval are significant factors restraining the Taiwan IVD market growth.

Introduction of Point-of-Care Testing (POCT) solutions creates opportunities for the Taiwan in-vitro diagnostics market in the coming future.

Download Free Sample

Phone Number *

Please enter Country Code and Phone No

Yes, I have read the Privacy Policy

Multi User

$2,575

Single User

$1,575

Enterprise

$3,875

Datapack

$1,975

Download Sample

Inquire Before Buying